Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,888 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Leadership development practices and hospital financial outcomes.
Crowe D, Garman AN, Li CC, Helton J, Anderson MM, Butler P. Crowe D, et al. Among authors: butler p. Health Serv Manage Res. 2017 Aug;30(3):140-147. doi: 10.1177/0951484817702564. Epub 2017 Apr 10. Health Serv Manage Res. 2017. PMID: 28391712
Leadership.
Garman AN, Butler P, Brinkmeyer L. Garman AN, et al. Among authors: butler p. J Healthc Manag. 2006 Nov-Dec;51(6):360-4. J Healthc Manag. 2006. PMID: 17184000 No abstract available.
Outcomes in facial transplantation - A systematic review.
Hadjiandreou M, Pafitanis G, Butler PM. Hadjiandreou M, et al. Among authors: butler pm. Br J Oral Maxillofac Surg. 2024 Feb 28:S0266-4356(24)00050-0. doi: 10.1016/j.bjoms.2024.02.008. Online ahead of print. Br J Oral Maxillofac Surg. 2024. PMID: 38637216 Review.
Correlation between oral and oropharyngeal resection subsites and impact of reconstruction on speech and swallowing function in head and neck cancer patients: A systematic review.
Awad L, Langridge BJ, Noy D, Govender R, Sinha D, Butler PE, Kalavrezos N. Awad L, et al. Among authors: butler pe. J Craniomaxillofac Surg. 2024 Jan 18:S1010-5182(24)00022-2. doi: 10.1016/j.jcms.2024.01.010. Online ahead of print. J Craniomaxillofac Surg. 2024. PMID: 38627188 Review.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: butler p. Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12. Lancet Oncol. 2024. PMID: 38621400 Clinical Trial.
1,888 results